Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBRIEF COMMUNICATION

Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma

Christina Laschinsky, Sarah Theurer, Thomas Herold, Josefine Rawitzer, Frank Weber, Ken Herrmann, Tim Brandenburg, Dagmar Führer-Sakel, Wolfgang P. Fendler and Manuel Weber
Journal of Nuclear Medicine December 2023, 64 (12) 1865-1868; DOI: https://doi.org/10.2967/jnumed.123.266044
Christina Laschinsky
1Department of Nuclear Medicine, University Hospital Essen, Essen, Germany;
2German Cancer Consortium, Partner Site Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Theurer
2German Cancer Consortium, Partner Site Essen, Essen, Germany;
3Institute of Pathology, University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Herold
2German Cancer Consortium, Partner Site Essen, Essen, Germany;
3Institute of Pathology, University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josefine Rawitzer
2German Cancer Consortium, Partner Site Essen, Essen, Germany;
3Institute of Pathology, University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Weber
2German Cancer Consortium, Partner Site Essen, Essen, Germany;
4Department of Surgery, Section of Endocrine Surgery, Essen University Hospital, Essen, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Herrmann
1Department of Nuclear Medicine, University Hospital Essen, Essen, Germany;
2German Cancer Consortium, Partner Site Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Brandenburg
2German Cancer Consortium, Partner Site Essen, Essen, Germany;
5Department of Endocrinology, Diabetes, and Metabolism, University Hospital Essen, University of Duisburg–Essen, Essen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dagmar Führer-Sakel
2German Cancer Consortium, Partner Site Essen, Essen, Germany;
5Department of Endocrinology, Diabetes, and Metabolism, University Hospital Essen, University of Duisburg–Essen, Essen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang P. Fendler
1Department of Nuclear Medicine, University Hospital Essen, Essen, Germany;
2German Cancer Consortium, Partner Site Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Weber
1Department of Nuclear Medicine, University Hospital Essen, Essen, Germany;
2German Cancer Consortium, Partner Site Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Kaplan–Meier curves showing time to RR-TC based on presence of BRAFV600E (A), TERT promoter (B), and TP53 (C) mutations.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1.

    Patient Characteristics

    CharacteristicData
    Sex
     Male18 (47%)
     Female20 (53%)
    Mean age (y)44.6 (13–79)
    UICC stage
     I27 (71%)
     II6 (16%)
     III1 (3%)
     IV4 (10%)
    Mean 131I activity (GBq)9.4 (0–50.0)
    Mean 124I activity (MBq)22.6 (0–39.8)
    Mean 18F-FDG activity (MBq)278.1 (170–460)
    Occurrence of RR-TC
     No27 (71%)
     Yes11 (29%)
    Median time to RR-TC (y)4.3 (0–19.8)
    Histopathologic subtype
     Classic19 (50%)
     FVPTC10 (26%)
     Tall cell3 (8%)
     Mixed classic/FVPTC6 (16%)
    Initial mean Tg level (ng/mL)113.71 (<0.03–1,236)
    • UICC = Union for International Cancer Control; FVPTC = follicular variant of PTC; Tg = thyroglobulin.

    • Qualitative data are number and percentage; continuous data are mean or median and range.

    • View popup
    TABLE 2.

    Prevalence of Genetic Alterations in Patient Cohort

    MutationOccurrence in 38 samples (n)
    BRAFV600E24 (63%)
    TERT promotor6 (16%)
    Tp538 (21%)
    APC2 (5%)
    KRAS0 (0%)
    HRAS0 (0%)
    NRAS0 (0%)
    RET1 (3%)
    DICER1 (3%)
    PTEN1 (3%)
    PDGRFA1 (3%)
    ERBB20 (0%)
    NF11 (3%)
    SCLC16A20 (0%)
    MET0 (0%)

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (12)
Journal of Nuclear Medicine
Vol. 64, Issue 12
December 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma
Christina Laschinsky, Sarah Theurer, Thomas Herold, Josefine Rawitzer, Frank Weber, Ken Herrmann, Tim Brandenburg, Dagmar Führer-Sakel, Wolfgang P. Fendler, Manuel Weber
Journal of Nuclear Medicine Dec 2023, 64 (12) 1865-1868; DOI: 10.2967/jnumed.123.266044

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma
Christina Laschinsky, Sarah Theurer, Thomas Herold, Josefine Rawitzer, Frank Weber, Ken Herrmann, Tim Brandenburg, Dagmar Führer-Sakel, Wolfgang P. Fendler, Manuel Weber
Journal of Nuclear Medicine Dec 2023, 64 (12) 1865-1868; DOI: 10.2967/jnumed.123.266044
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Bioanalytic Hybrid System Merging 3-Dimensional Cell Culture and Chromatographic Precision for Unprecedented Preclinical Insights in Molecular Imaging
  • Radiances of Cerenkov-Emitting Radionuclides on the In Vivo Imaging System
  • Measuring Total Metabolic Tumor Volume from 18F-FDG PET: A Reality Check
Show more BRIEF COMMUNICATION

Similar Articles

Keywords

  • molecular imaging
  • radionuclide therapy
  • molecular alterations
  • papillary thyroid cancer
  • radioiodine refractoriness
  • TP53
SNMMI

© 2025 SNMMI

Powered by HighWire